An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment

Simple item page
dc.contributor.authorSimsek F.
dc.contributor.authorInan S.
dc.contributor.authorKorkmaz M.
dc.date.accessioned2024-07-22T08:08:58Z
dc.date.available2024-07-22T08:08:58Z
dc.date.issued2019
dc.description.abstractObjectives: We aimed to investigate the distribution of immunoreactivities of vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), and inducible NOS (iNOS) on breast cancer cells in response to treatment with boron derivatives. Methods: We initially analyzed the cytotoxic effect and IC50 value of boron by MTT assay. For the evaluation of the angiogenesis, expression level of antibodies was detected to following boron derivatives such as boric acid, boron penta (BP), and T-Boron (DPD) in the absence of boron treatment using the indirect immunohistochemical method. The evaluation of these staining was done using the H-scoring system. Results: It was found that immunoreactivities of VEGF, eNOS, and iNOS increased on control compared to those of the cells of MDA-MB231 human breast cancer cell line. Following boron derivatives treatment, it was observed that they were inhibited the VEGF/NOS labeling in MDA-MB-231 breast cancer cells. Conclusion: The present data suggest that BP, especially DPD, inhibits the angiogenesis of breast cancer cells through VEGF pathway. From this point, these boron derivatives may provide a novel therapeutic approach for breast cancer treatment. © 2019, by Eurasian Journal of Medicine and Oncology.
dc.identifier.DOI-ID10.14744/ejmo.2018.0020
dc.identifier.issn25872400
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14590
dc.language.isoEnglish
dc.publisherKare Publishing
dc.rightsAll Open Access; Gold Open Access
dc.titleAn in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment
dc.typeArticle

Files

Collections

Scopus Koleksiyonu